2023
The Choice of Anticoagulant at First Recurrence Does Not Alter the Risk for the Second Recurrence
Muradashvili T, Restrepo V, Alameddine D, Soliman S, Feinn R, Chaar C, Lee A, Pine A. The Choice of Anticoagulant at First Recurrence Does Not Alter the Risk for the Second Recurrence. Blood 2023, 142: 5540. DOI: 10.1182/blood-2023-191084.Peer-Reviewed Original ResearchFirst VTE recurrenceDeep venous thrombosisFirst venous thromboembolismRecurrent VTE eventsVTE recurrenceVenous thromboembolismPulmonary embolismAnticoagulation regimenVTE eventsAnticoagulant regimenFirst recurrenceINR targetSecond recurrenceExact testFirst recurrent venous thromboembolismInferior vena cava atresiaLarge tertiary academic hospitalUnprovoked first venous thromboembolismMajor public health hazardDifferent anticoagulant agentsInterruption of anticoagulationCardiovascular risk factorsMay-Thurner syndromePatients 18 yearsRecurrent venous thromboembolism
2009
Rituximab Does Not Improve Progression Free (PFS) or Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell Lymphoma (DLBCL).
Hochberg E, Birrer N, Toomey C, Barnes J, Lee A, LaCasce A, Abramson J. Rituximab Does Not Improve Progression Free (PFS) or Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell Lymphoma (DLBCL). Blood 2009, 114: 3755. DOI: 10.1182/blood.v114.22.3755.3755.Peer-Reviewed Original ResearchLimited stage diffuse large B-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaUse of rituximabOverall survivalB-cell lymphomaSpeakers bureauCell lymphomaYounger low-risk patientsPrimary diffuse large B-cell lymphomaDana-Farber Cancer InstituteBenefit of rituximabGood-prognosis populationMultiple retrospective analysesAnthracycline-containing chemotherapyOverall survival benefitPatients 18 yearsLow-risk patientsAdvanced-stage patientsCD20 monoclonal antibodyLarge multicenter trialsTumor registry dataYears of ageMassachusetts General HospitalCurative intent